Avicanna and Medipharm Labs Expand Strategic Manufacturing Agreement for Avicanna’s Proprietary SEDDS Technology Capsules for Canadian and International markets
26 6월 2023 - 8:30PM
Avicanna Inc. (“
Avicanna” or the
“
Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a
biopharmaceutical company focused on the development, manufacturing
and commercialisation of plant-derived cannabinoid-based products
is pleased to announce the extension of its existing strategic
manufacturing agreement with Medipharm Labs Inc.
(“
MediPharm”) for the commercialization of
Avicanna’s proprietary cannabinoid-based Self-Emulsifying Drug
Delivery Systems (“
SEDDS”) technology capsules for
the Canadian and international markets.
“We are happy to be advancing our proprietary
SEDDS technology capsules to the market with MediPharm, who have
demonstrated focus, alignment and the necessary capabilities to
manufacture and deliver these products across a number of markets
and channels. We are excited about the potential of our proprietary
single-dose formulations in both medical and pharmaceutical
cannabinoid segments,” stated Aras Azadian, CEO of Avicanna.
Canadian commercialization under Good
Production Practices (“GPP”)
Under the expanded Strategic Manufacturing
Agreement, Avicanna intends to commercialize its proprietary SEDDS
technology capsules, under the RHO Phyto brand, across domestic
nation-wide medical channels including the Avicanna’s MyMedi.ca
online cannabis care platform and MediPharm’s Canna farms platform.
Additionally, MediPharm intends to commercialize the capsules
across adult use wellness channels under its MediPharm Labs
brand.
International and pharmaceutical
potential under Good Manufacturing Practices (“GMP”)
MediPharm intends to manufacture these
proprietary capsules in accordance with GMP standards to fulfill
domestic and international pharmaceutical standards. The expanded
Strategic Manufacturing Agreement provides that each of Avicanna
and MediPharm may take steps towards offering these products
internationally through existing internal infrastructure and
externally with parties under contract.
About the SEDDS capsules
Due to the highly lipophilic nature and poor
water-solubility of cannabinoids, the formulations currently
available in the Canadian market have been generally described as
having poor absorption and high variability of onset. SEDDS oral
delivery systems offer an effective route for non-invasive and
non-inhalation administration of cannabinoids1-4. Avicanna’s
proprietary SEDDS technology demonstrated shelf-life stability with
more than 90% of the total cannabinoid(s) remaining after 6 months
in accelerated conditions. The formulation’s CBD and THC
dissolution profiles were also tested in biorelevant media which
mimic human intestinal fluid and demonstrated more than 90%
dispersion within one hour with continued stabilization of the
emulsion. The company plans to advance specific formulations into
pre-clinical and clinical development.
About Avicanna Inc.
Avicanna is a commercial-stage international
biopharmaceutical company focused on the advancement and
commercialization of evidence-based cannabinoid-based products for
the global medical and pharmaceutical market segments. Avicanna has
an established scientific platform including R&D and clinical
development that has led to the commercialization of more than
thirty products across various market segments:
- Medical Cannabis &
Wellness Products (RHO
Phyto™): The
formulary offers a diverse range of proprietary formulations
including oral, sublingual, topical, and transdermal deliveries
with varying ratios of cannabinoids and is supported with ongoing
patient, and medical community education. RHO Phyto has been
established as a leading medical brand in Canada and is currently
available nationwide to patients across several medical channels
and continues to expand into new international markets.
- Pharmaceutical Preparations
and Pipeline: Leveraging Avicanna’s
scientific platform, vertical integration, and real-world evidence,
Avicanna has developed an extensive a pipeline of patent-pending
drug candidates that are indication-specific and in various stages
of clinical development and commercialization. These
cannabinoid-based drug candidates look to address unmet medical
needs in the areas of dermatology, chronic pain, and various
neurological disorders. Avicanna’s first pharmaceutical preparation
(Trunerox™) is in the drug registration stage in South
America.
- MyMedi.ca
Medical Cannabis Care Portal:
MyMedi.ca is Avicanna’s medical cannabis care platform that is
formed with the aim to better serve medical cannabis patients’
needs and enhance the patient journey. MyMedi.ca is expected to
launch during August 2023 and will feature diverse and
scientifically curated products from leading Canadian licensed
producers in addition to pharmacist led patient support programs
and educational resources to facilitate the incorporation of
medical cannabis into health care regimens. MyMedi.ca also provides
specialty services to distinct patient groups such as veterans and
collaborating with public and private providers for adjudication
and reimbursement.
Click to watch Avicanna’s Corporate Video 2022
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit our
website, contact Ivana Maric by email at info@avicanna.com or
follow us on social media
on LinkedIn, Twitter, Facebook, or Instagram.
The Company posts updates through videos from
the Company YouTube channel.
Cautionary Note Regarding Forward-Looking Information
and Statements
This news release contains “forward-looking
information” within the meaning of applicable securities laws.
Forward-looking information contained in this news release may be
identified using words such as, “may”, “would”, “could”, “will”,
“likely”, “expect”, “anticipate”, “believe, “intend”, “plan”,
“forecast”, “project”, “estimate”, “outlook” and other similar
expressions. Although the Company believes that the expectations
and assumptions on which such forward looking information is based
are reasonable, undue reliance should not be placed on the
forward-looking information because the Company can give no
assurance that they will prove to be correct. Actual results and
developments may differ materially from those contemplated by these
statements. Forward-looking information is subject to a variety of
risks and uncertainties that could cause actual events or results
to differ materially from those projected in the forward-looking
information. Such risks and uncertainties include but are not
limited to current and future market conditions, including the
market price of the common shares of the Company, and the risk
factors set out in the Company’s annual information form dated
March 31, 2023 filed with the Canadian securities regulators and
available under the Company’s profile on SEDAR at www.sedar.com.
The statements in this news release are made as of the date of this
release. The Company disclaims any intent or obligation to update
any forward-looking information, whether as a result of new
information, future events or results or otherwise, other than as
required by applicable securities laws.
References:
- I. Maji, et al., Solid self
emulsifying drug delivery system: Superior mode for oral delivery
of hydrophobic cargos. Journal of Controlled Release, 337,
2021;646-660.
- Salawi A. Self-emulsifying drug
delivery systems: a novel approach to deliver drugs. Drug Deliv.
2022 Dec;29(1):1811-1823.
- Khaled, A.; Ayat, A. A.; Mahmoud,
E.-B., Self-Emulsifying Drug Delivery Systems: Easy to Prepare
Multifunctional Vectors for Efficient Oral Delivery. In Current and
Future Aspects of Nanomedicine, Islam Ahmed Hamed, K., Ed.
IntechOpen: Rijeka, 2019; p Ch. 4
- Pathak, Ashish Kumar et al. “Recent
advances in self emulsifying drug delivery system - A review.” Drug
Invention Today (2010): 123-129.
Avicanna (TSX:AVCN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Avicanna (TSX:AVCN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024